Focus on Life-Threatening Bleeds in Patients on Direct Factor Xa-Inhibitors

Medication-use evaluations (MUEs) are an important quality improvement tool. Therefore, the ASHP Foundation convened a multidisciplinary advisory panel of experts to create the Medication-Use Evaluation Resource Guide: Andexanet Alfa in the Management of Life-Threatening Bleeds in Patients on Direct Factor Xa-Inhibitors.

The advisory panel found that applying the FOCUS-PDCA model from the ASHP MUE Guidelines enhances the rigor of MUEs and supports organizations to meet goals, including to optimize medication use, reduce process variation, decrease waste, and enhance value.

While the application of the FOCUS-PDCA framework in the resource guide is focused on a specific anticoagulant reversal agent, users will customize the included MUE templates to meet their organizational goals and can apply the framework to other drugs and clinical scenarios.

The creation of the MUE Resource Guide was supported by Alexion.